Exhaustive Study Guide on Diabetes Mellitus and Hypoglycemia

Introduction to Diabetes Mellitus and Pancreatic Function

Definitions and Overview: * Diabetes Mellitus (DM): A condition of chronic hyperglycemia resulting from problems with glucose regulation. * Underlying Problem: A fundamental lack of insulin, which is a hormone needed to move glucose from the bloodstream into the cells for energy. * Healthy State: In a healthy individual, the body breaks down carbohydrates into blood sugar (glucose), and insulin facilitates its entry into cells via insulin receptors.
Pancreatic Pathophysiology: * Alpha Cells: These cells secrete glucagon, which works to prevent hypoglycemia (low blood glucose). * Beta Cells: These cells produce insulin and amylin, which work to prevent hyperglycemia (high blood glucose). * The "Gas and Brake" Metaphor: The alpha and beta cells work together like a gas and brake system to maintain glucose homeostasis. * Commonality: Regardless of the specific type of DM, the underlying insufficiency in pancreatic beta cell function leads to the same organ-damaging consequences and complications of impaired glucose regulation.

Classification and Pathophysiology of Diabetes Types

Type 1 Diabetes Mellitus (T1DM): * Characterization: The body does not produce insulin. It is an autoimmune disorder where pancreatic beta cells are destroyed. * Mechanism: The immune system fails to recognize normal body cells as "self," and immune cells and antibodies take destructive actions against insulin-secreting cells in the islets. * Triggers: Viral infections such as mumps, coxsackievirus, and COVID-19 may trigger these autoimmune destructive actions.
Type 2 Diabetes Mellitus (T2DM): * Characterization: The body does not use insulin properly (insulin resistance), and the condition is progressive. * Mechanism: Insulin resistance is a reduced cell receptor response to insulin. It progresses to decreased beta cell secretion of insulin. * Cardiovascular Correlation: It often develops in genetically susceptible adults and is accompanied by hyperlipidemia, hypertension, and increased clot formation. * Environmental Factors: Developmental factors include neighborhood safety, walkability, food security, air quality, and overall access to health care.
Other Forms of Diabetes: * Latent Autoimmune Diabetes of Adulthood (LADA): Often called "Type 1.5," this is a slow, progressive autoimmune form of diabetes with varying degrees of insulin resistance, typically diagnosed in patients older than $30$ years of age. * Maturity-Onset Diabetes of the Young (MODY): An inherited mutation in one of at least six known genes resulting in loss of insulin function and hyperglycemia. It is not an autoimmune issue and resembles T1DM in insulin requirements and DKA potential, usually diagnosed in young adults but can appear at any time. * Gestational Diabetes Mellitus (GDM): Glucose intolerance with onset or first recognition during pregnancy. All pregnant women should be screened.

Comparison of Risk Factors and Manifestations

Type 1 Risk Factors: * Family history and genetics. * Geography. * Age: Typically diagnosed in individuals less than $30$ years of age. Peak onset occurs between $4 - 7$ years and again between $10 - 14$ years. * Body Type: Usually not obese. * Onset: Abrupt.
Type 2 Risk Factors: * Weight: Obesity is a primary factor. * Family history. * Inactivity. * Age: Peaks around age $50$ . * Onset: Insidious (gradual and very slow). * Cultures: Higher prevalence in Hispanic, African American, Native American, Asian American, and Pacific Islander populations. * Medical History: History of gestational diabetes.
Clinical Manifestations (Hyperglycemia): * Without insulin, glucose builds up in the blood, causing hyperglycemia, which disturbs fluid and electrolyte balance. * The 3 P’s: * Polyuria: Frequent and excessive urination. * Polydipsia: Excessive thirst. * Polyphagia: Excessive eating. * Weight Changes: T1DM often involves weight loss with pronounced symptoms; T2DM often involves weight gain with less obvious symptoms.
Priority Body Systems Involved: * Endocrine system. * Renal (Kidneys). * Neuromuscular. * Visual (Eyes).

Laboratory Diagnostics and Assessment

Diagnostic Standards and Values: * Normal Fasting Glucose: $70 - 110\,mg/dL$ . * Post-Prandial (After Meals) Glucose: Target is less than $180\,mg/dL$ . * Hemoglobin A1C (AIC): Target for normal/well-controlled is less than $6$ . * Other Diagnostics: Glucose tolerance tests, urine screening for glucose/ketones.
Comprehensive Assessment Findings: * Skin: Breaks in skin, infection, diabetic dermopathy, and unhealed injection sites. * Eyes: Cataracts and retinal problems. * Peripheral Vascular/Neuropathy: Hair loss on extremities; thin, shiny, pale, cool skin; weak or absent pulses; thick nails; erectile disorder. * Cardiac: Angina, Myocardial Infarction (MI), and cardiovascular disease. * Neuro: Stroke signs. * Respiratory: Dyspnea (shortness of breath). * Kidneys: Edema, Urinary Tract Infections (UTI), and urinary retention. * GI/Oral: Dental caries, periodontal disease, and Candidiasis.

Pharmacological Management: Insulin Therapy

Rapid-Acting Insulin (Bolus): * Examples: Human Lispro (Humalog), Insulin Aspart (Novolog), Insulin Glulisine (Apidra). * Onset: Within $5 - 15\,minutes$ . * Peak: Approximately $1\,hour$ . * Administration: Given just prior to, during, or within $20\,minutes$ after a meal. The nurse must be certain a meal will be ingested because of the rapid onset.
Short-Acting Insulin: * Example: Regular Human Insulin (Humulin R, Novolin R). * Onset: $30 - 60\,minutes$ . * Peak: $2 - 4\,hours$ . * Duration: $5 - 7\,hours$ . * Note: This is the only kind of insulin that can be used intravenously (IV). It is used for sliding scales and DKA emergencies.
Intermediate-Acting Insulin: * Example: NPH (Humulin N, Novolin N). * Onset: $1 - 2\,hours$ . * Peak: $4 - 12\,hours$ (it is critical to "plate" or ensure food intake during the peak). * Duration: $18 - 24\,hours$ . * Mixing: When mixing with other insulins, always draw clear (Short-acting) before cloudy (NPH). Between-meal snacks may be necessary to prevent hypoglycemia.
Long-Acting Insulin (Basal): * Example: Insulin Glargine (Lantus). * Onset: $2 - 4\,hours$ . * Peak: Relatively constant slow release; approximately $12\,hours$ . * Duration: $24\,hours$ . * Restrictions: Cannot be mixed with any other insulin. It must be administered within $30\,minutes$ of the same time each day. It generally does not cause hypoglycemia even when NPO.
Injection Site Rotation: * Site affects absorption speed; the abdomen is the fastest and preferred site, excluding a $2-inch$ radius around the navel. * Rotation is required to allow healing of each site.

Non-Insulin Pharmacological Agents

Oral Hypoglycemic Agents: * Secretagogues (Sulfonylureas): Trigger release of preformed insulin from beta cells. Examples: Glipizied, Glyburide. * Sensitizers (Thiazolidinediones): Decrease liver glucose production and improve insulin receptor sensitivity. Examples: Pioglitazone, Rosiglitazone. * Biguanide (Metformin): Inhibits liver glucose production, decreases intestinal absorption of glucose, and increases insulin sensitivity. * Patient Safety for Metformin: Avoid alcohol (risk of lactic acidosis). Discontinue $48\,hours$ before and after imaging tests using contrast agents to avoid kidney damage. Common side effects are GI-related. * Slow Absorption Agents: Pramlintide.
Semaglutides / Incretin Mimetics (GLP-1 Agonists): * Mechanisms: Reduce pancreatic glucagon secretion, reduce liver glucose production, and delay gastric emptying. * Examples: Dulaglutide, Exenatide (and Extended Release), Liraglutide, Lixisenatide, Semaglutide. * Dosing: Some are weekly (Exenatide, Dulaglutide, injected Semaglutide) rather than daily. * Risk Warning: Increased risk for pancreatitis (report persistent abdominal pain and nausea) and contraindicated in gastroparesis.

Patient Education and Interventions

Foot Care Education: * Inspect feet daily, especially between toes. Wash with lukewarm water and soap; dry thoroughly. * Moisturize feet but NOT between toes. Wear clean cotton socks and breathable shoes (leather/cloth). * Change shoes daily; do not wear the same pair two days in a row. Check for foreign objects (pebbles) and lining tears before wearing. * Buy shoes later in the day when feet are larger; ensure plenty of room for toes. Break in shoes gradually. * Trim nails straight across; smooth with an emery board. * Contraindications: Do not go barefoot, wear sandals with open toes or straps between toes, use home remedies for corns/calluses, or use heating pads/portable heaters/hot-water bottles on feet. * Injury Protocol: Protect sores with a dry sterile dressing; do NOT use tape on the skin. See provider immediately for blisters or infections.
Sick Day Rules: * Notify the healthcare provider of illness. Monitor blood glucose every $2 - 4\,hours$ . * Test urine for ketones even if glucose is in range, especially if vomiting. * Continue taking insulin or antidiabetic agents unless instructed otherwise. * Prevent dehydration: Drink $8 - 12\,ounces$ ( $240 - 360\,mL$ ) of sugar-free fluid every hour while awake. If blood glucose is low, drink fluids containing sugar. * Call provider if: Persistent nausea/vomiting, persistent hypoglycemia, moderate/high ketones, temperature above $101.5^{\circ}F$ ( $38.6^{\circ}C$ ), or fever lasting more than $24\,hours$ .
Nutritional Guidelines: * Eat at least $25\,g$ of fiber daily. Avoid sugar-sweetened beverages and high fructose corn syrup. * Mediterranean-style diets (MUFAs, avocados, nuts, olives) can lower cardiac risk. * Omega-3 fatty acids (EPA, DHA from fish/oil and ALA from plants) are recommended. * Carbohydrate Counting: A common ratio is $1\,unit$ of rapid-acting insulin for every $15\,g$ of carbohydrates (CHO). Patients must read labels and weigh/measure items to calculate the bolus dose.

Morning Hyperglycemia: Dawn Phenomenon vs. Somogyi Effect

Dawn Phenomenon: * Definition: Normal early-morning hyperglycemia caused by the circadian release of hormones (growth hormone, cortisol, glucagon) to prepare the body to wake up. * Mechanism: Glucagon release causes blood sugar to rise, but the diabetic patient lacks enough insulin to counteract it. * Treatment: Increase insulin or change administration time; diet/carb management.
Somogyi Effect: * Definition: Morning hyperglycemia occurring as a rebound from untreated overnight hypoglycemia. * Symptoms: Night sweats, morning headaches, nightmares, ketonuria, feeling weak and sweaty. * Mechanism: Blood sugar drops too low during the night (possibly from too much insulin or missing a snack). The body reacts by releasing glucagon, leading to rebound hyperglycemia. * Treatment: Give a bedtime snack or reduce insulin at bedtime; track glucose and snacks.

Hypoglycemia: Pathophysiology and Management

Thresholds: * Low blood glucose: Less than $70\,mg/dL$ . * Severe hypoglycemia: Less than $50\,mg/dL$ (some sources define severe/emergency as less than $20\,mg/dL$ ).
Clinical Signs (Neurogenic vs. Neuroglycopenic): * Neurogenic (Early Warning): Sweating (cholinergic), irritability, tremors, anxiety (adrenergic), tachycardia, heart pounding, hunger, and tingling. * Neuroglycopenic (Brain Deprivation): Weakness, fatigue, difficulty thinking, confusion, behavior changes, seizures, coma, permanent brain damage, and death.
The 15-15 Rule for Management: * If blood glucose is $< 70\,mg/dL$ : Give $15\,g$ of fast-acting carbohydrates. * If blood glucose is $< 50\,mg/dL$ : Give $30\,g$ of fast-acting carbohydrates. * Recheck blood glucose in $15\,minutes$ . If still low, repeat treatment. * Once above hypoglycemic range, follow up with a complex carbohydrate (e.g., crackers with nut butter). * Fast-Acting Sources: Liquids are preferred if the patient can swallow. Avoid high-potassium orange juice or high-fat chocolate (which slows absorption).
Severe Hypoglycemia Management: * If patient is unresponsive or unable to swallow: Administer IV concentrated dextrose or intramuscular/subcutaneous glucagon. * Home/Family Care: Give prescribed glucagon; give a second dose in $10\,minutes$ if still unconscious. Notify provider and transport to ED if necessary.

Questions & Discussion

Scenario 1: NCLEX Practice Question (Insulin Calculation) * Client: Type 1 DM, admitted for pneumonia. Blood glucose is $155\,mg/dL$ . * Meal: Grilled chicken breast ( $0\,g$ ), Brown Rice ( $24\,g$ ), Steamed broccoli ( $6\,g$ ), Whole wheat dinner roll ( $15\,g$ ), Apple slices ( $15\,g$ ), Water ( $0\,g$ ). * Orders: $1\,unit$ Regular insulin for every $15\,g$ CHO. Sliding scale: Give $2\,units$ for blood glucose between $151 - 200\,mg/dL$ . * Calculation: 1. Total CHO = $24 + 6 + 15 + 15 = 60\,g$ . 2. Carb units = $60 / 15 = 4\,units$ . 3. Sliding scale units (for $155\,mg/dL$ ) = $2\,units$ . * Total Administration: $4 + 2 = 6\,units$ .
Scenario 2: NCLEX Practice Question (Hypoglycemia Priority) * Client: Type 1 DM, tearful, diaphoretic, reports hunger. * Question: What should the nurse do first? * Options: 1. Monitor vital signs; 2. Measure urine output; 3. Check capillary blood glucose; 4. Prepare scheduled insulin. * Correct Action: Option 3: Check the client’s capillary blood glucose level immediately to confirm hypoglycemia before intervening (Jittery, clammy, shaky: CHECK BS immediately!).
Summary of Key Takeaways: * Type 1 is usually childhood onset; Type 2 is elderly/adult and progressive. * Diet and exercise are essential for both. * Regular monitoring is vital. * Nurses should teach and support, never shame for difficult glucose maintenance. * Social determinants of health (income, education, culture) significantly impact adherence.